HUTCHMED (China) Limited (HKG:0013)

Market Cap	19.43B
Revenue (ttm)	4.73B
Net Income (ttm)	3.67B
Shares Out	n/a
EPS (ttm)	4.16
PE Ratio	5.30
Forward PE	11.27
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,891,500
Average Volume	5,449,783
Open	22.60
Previous Close	22.82
Day's Range	21.58 - 22.60
52-Week Range	18.36 - 30.75
Beta	0.51
RSI	29.61
Earnings Date	Nov 13, 2025

About HUTCHMED (China)

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 1,811
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 0013

Financial Performance

In 2024, HUTCHMED (China)'s revenue was $630.20 million, a decrease of -24.80% compared to the previous year's $838.00 million. Earnings were $37.73 million, a decrease of -62.56%.

Financial numbers in USD